Skip to main content

Table 3 Treatment and outcomes of patients with ILD and a positive anti-Ro52 antibody, stratified by ICU vs non-ICU (e.g. hospital or clinic) presentation at the time of anti-Ro52 lab testing. Pharmacotherapy includes all medications given, including in combination. Antifibrotic therapy includes medications approved for the treatment of idiopathic pulmonary fibrosis, including pirfenidone or nintedanib. Mortality is all-cause

From: Presentations and outcomes of interstitial lung disease and the anti-Ro52 autoantibody

Variable All patients
n = 73
ICU presentation
n = 13
Non-ICU presentation
n = 60
Age, years median [range] 68 [23–90] 60 [43–86] 69 [23–90]
Male, n (%) 45 (61.6%) 10 (76.9%) 35 (58.3%)
Ethnicity, n (%)
 African American 7 (9.6%) 2 (15.4%) 5 (8.3%)
 Asian 6 (8.2%) 2 (15.4%) 4 (6.7%)
 Hispanic 4 (5.5%) 0 (0%) 4 (6.7%)
 White 56 (76.7%) 9 (69.2%) 47 (78.3%)
Smoking history, n (%)
 Current/Former 43 (58.9%) 10 (76.9%) 33 (55%)
 Never 30 (41.1%) 3 (23.1%) 27 (45%)
Pharmacotherapy, n (%)
 Corticosteroids 45 (61.6%) 13 (100%) 32 (53.3%)
 Rituximab 19 (26.0%) 2 (15.4%) 17 (28.3%)
 IVIG 8 (11%) 4 (30.8%) 4 (6.7%)
 Mycophenolate 18 (24.7%) 2 (15.4%) 16 (26.7%)
 Cyclophosphamide 2 (2.7%) 1 (7.7%) 1 (1.7%)
 Antifibrotic 5 (6.9%) 0 (0%) 5 (8.3%)
Outcome, n (%)
 Improved 12 (16.4%) 2 (15.4%) 10 (16.7%)
 Stable 32 (43.8%)   32 (53.3%)
 Progressed 8 (11%)   8 (13.3%)
 Died 21 (28.8%) 11 (84.6%) 10 (16.7%)